146 related articles for article (PubMed ID: 11313401)
1. Sanglifehrin A, a novel cyclophilin-binding immunosuppressant, inhibits IL-2-dependent T cell proliferation at the G1 phase of the cell cycle.
Zhang LH; Liu JO
J Immunol; 2001 May; 166(9):5611-8. PubMed ID: 11313401
[TBL] [Abstract][Full Text] [Related]
2. Sanglifehrin A, a novel cyclophilin-binding compound showing immunosuppressive activity with a new mechanism of action.
Zenke G; Strittmatter U; Fuchs S; Quesniaux VF; Brinkmann V; Schuler W; Zurini M; Enz A; Billich A; Sanglier JJ; Fehr T
J Immunol; 2001 Jun; 166(12):7165-71. PubMed ID: 11390463
[TBL] [Abstract][Full Text] [Related]
3. The novel cyclophilin binding compound, sanglifehrin A, disassociates G1 cell cycle arrest from tolerance induction.
Allen A; Zheng Y; Gardner L; Safford M; Horton MR; Powell JD
J Immunol; 2004 Apr; 172(8):4797-803. PubMed ID: 15067056
[TBL] [Abstract][Full Text] [Related]
4. Cutting edge: sanglifehrin A, a novel cyclophilin-binding immunosuppressant blocks bioactive IL-12 production by human dendritic cells.
Steinschulte C; Taner T; Thomson AW; Bein G; Hackstein H
J Immunol; 2003 Jul; 171(2):542-6. PubMed ID: 12847216
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the new immunosuppressive drug undecylprodigiosin in human lymphocytes: retinoblastoma protein, cyclin-dependent kinase-2, and cyclin-dependent kinase-4 as molecular targets.
Songia S; Mortellaro A; Taverna S; Fornasiero C; Scheiber EA; Erba E; Colotta F; Mantovani A; Isetta AM; Golay J
J Immunol; 1997 Apr; 158(8):3987-95. PubMed ID: 9103470
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive activity of the immunophilin-binding drug Sanglifehrin A in human whole blood: potent inhibition of interleukin-6 produced by lymphocytes and monocytes.
Härtel C; Iblher P; Puzik A; Wortmeier K; Ebel B; Schultz C; Müller-Steinhardt M
Scand J Immunol; 2006 Jan; 63(1):26-34. PubMed ID: 16398698
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of the immunosuppressant rapamycin.
Dumont FJ; Su Q
Life Sci; 1996; 58(5):373-95. PubMed ID: 8594303
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin.
Nourse J; Firpo E; Flanagan WM; Coats S; Polyak K; Lee MH; Massague J; Crabtree GR; Roberts JM
Nature; 1994 Dec; 372(6506):570-3. PubMed ID: 7990932
[TBL] [Abstract][Full Text] [Related]
9. V3 loop of human immunodeficiency virus type 1 reduces cyclin E expression and induces G1 arrest in interleukin 2-dependent T cells.
Sakaida H; Kawamata S; Hattori T; Uchiyama T
AIDS Res Hum Retroviruses; 1998 Jan; 14(1):31-8. PubMed ID: 9453249
[TBL] [Abstract][Full Text] [Related]
10. Sanglifehrin-cyclophilin interaction: degradation work, synthetic macrocyclic analogues, X-ray crystal structure, and binding data.
Sedrani R; Kallen J; Martin Cabrejas LM; Papageorgiou CD; Senia F; Rohrbach S; Wagner D; Thai B; Jutzi Eme AM; France J; Oberer L; Rihs G; Zenke G; Wagner J
J Am Chem Soc; 2003 Apr; 125(13):3849-59. PubMed ID: 12656618
[TBL] [Abstract][Full Text] [Related]
11. Dentritic cell derived IL-18 production is inhibited by rapamycin and sanglifehrin A, but not cyclosporine A.
Ko H; Hambly BD; Eris JM; Levidiotis V; Wyburn K; Wu H; Chadban SJ; Yin JL
Transpl Immunol; 2008 Nov; 20(1-2):99-105. PubMed ID: 18662782
[TBL] [Abstract][Full Text] [Related]
12. Molecular basis for the lack of T cell proliferation induced by an altered peptide ligand.
Grakoui A; VanDyk LF; Dowdy SF; Allen PM
Int Immunol; 1998 Jul; 10(7):969-79. PubMed ID: 9701035
[TBL] [Abstract][Full Text] [Related]
13. The novel cyclophilin-binding drug sanglifehrin A specifically affects antigen uptake receptor expression and endocytic capacity of human dendritic cells.
Woltman AM; Schlagwein N; van der Kooij SW; van Kooten C
J Immunol; 2004 May; 172(10):6482-9. PubMed ID: 15128841
[TBL] [Abstract][Full Text] [Related]
14. Endogenous basic fibroblast growth factor is essential for cyclin E-CDK2 activity in multiple external cytokine-induced proliferation of AIDS-associated Kaposi's sarcoma cells: dual control of AIDS-associated Kaposi's sarcoma cell growth and cyclin E-CDK2 activity by endogenous and external signals.
Murakami-Mori K; Mori S; Nakamura S
J Immunol; 1998 Aug; 161(4):1694-704. PubMed ID: 9712033
[TBL] [Abstract][Full Text] [Related]
15. G1-checkpoint function including a cyclin-dependent kinase 2 regulatory pathway as potential determinant of 7-hydroxystaurosporine (UCN-01)-induced apoptosis and G1-phase accumulation.
Akiyama T; Sugiyama K; Shimizu M; Tamaoki T; Akinaga S
Jpn J Cancer Res; 1999 Dec; 90(12):1364-72. PubMed ID: 10665655
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolic acid inhibits IL-2-dependent T cell proliferation, but not IL-2-dependent survival and sensitization to apoptosis.
Quéméneur L; Flacher M; Gerland LM; Ffrench M; Revillard JP; Bonnefoy-Berard N
J Immunol; 2002 Sep; 169(5):2747-55. PubMed ID: 12193749
[TBL] [Abstract][Full Text] [Related]
17. Role of proteasomes in T cell activation and proliferation.
Wang X; Luo H; Chen H; Duguid W; Wu J
J Immunol; 1998 Jan; 160(2):788-801. PubMed ID: 9551914
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes.
Morice WG; Wiederrecht G; Brunn GJ; Siekierka JJ; Abraham RT
J Biol Chem; 1993 Oct; 268(30):22737-45. PubMed ID: 8226784
[TBL] [Abstract][Full Text] [Related]
19. Cyclophilin A is required for M-CSF-dependent macrophage proliferation.
Sànchez-Tilló E; Wojciechowska M; Comalada M; Farrera C; Lloberas J; Celada A
Eur J Immunol; 2006 Sep; 36(9):2515-24. PubMed ID: 16909430
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanism of cell cycle progression induced by the oncogene product Tax of human T-cell leukemia virus type I.
Iwanaga R; Ohtani K; Hayashi T; Nakamura M
Oncogene; 2001 Apr; 20(17):2055-67. PubMed ID: 11360190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
